外泌体在卵巢癌血管生成中的研究进展

doi:10.12280/gjfckx.20240329

摘要/Abstract

摘要：

在卵巢癌的治疗过程中，肿瘤细胞往往会对化疗药物产生耐药性，导致治疗效果减弱或消失。因此，抗血管生成治疗作为一种重要的维持治疗手段，通过不同的机制与其他治疗方法协同作用，可以有效减慢疾病进展速度。外泌体是由活细胞分泌的细胞外囊泡，携带着多种遗传物质，在肿瘤微环境中起着细胞通信的重要作用。研究发现，肿瘤细胞及其他细胞来源的外泌体可以通过释放非编码RNA、蛋白质等遗传物质影响血管生成及其他肿瘤相关过程。利用外泌体靶向特定蛋白或作为包裹治疗剂的外源性载体，已经成为卵巢癌抗血管生成治疗的重要策略。综述外泌体对卵巢癌血管生成的调控机制，以及其作为抗血管生成剂的作用潜力，以期为新的治疗方法提供理论依据。

关键词: 外泌体, 卵巢肿瘤, 新生血管化, 治疗, 肿瘤微环境

Abstract:

In the treatment of ovarian cancer, tumor cells often become resistant to chemotherapy drugs, leading to weakened or ineffective treatment outcomes. Therefore, anti-angiogenesis therapy serves as an important adjunctive treatment, can effectively slow disease progression by synergizing with other treatment modalities through various mechanisms. Exosomes, extracellular vesicles secreted by living cells, carry a variety of genetic materials and play crucial roles in cell communication within the tumor microenvironment. Studies have shown that exosomes derived from tumor cells and other cell sources can influence angiogenesis and other tumor-related processes by releasing non-coding RNAs, proteins, and other genetic materials. Utilizing exosomes to target specific proteins or as exogenous carriers for encapsulate therapeutic agents has become an important strategy for anti-angiogenesis therapy in ovarian cancer. This review summarized the regulatory mechanism of exosomes on angiogenesis in ovarian cancer and it also explores the potential of exosomes as anti-angiogenic agents, providing a theoretical basis for new treatment methods.

Key words: Exosomes, Ovarian neoplasms, Neovascularization, Therapy, Tumor microenvironment

张静怡, 刘东哲, 陈秀慧. 外泌体在卵巢癌血管生成中的研究进展[J]. 国际妇产科学杂志, 2024, 51(4): 370-374.

ZHANG Jing-yi, LIU Dong-zhe, CHEN Xiu-hui. Research Advances of Exosomes in Angiogenesis of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 370-374.

参考文献 36

[1]	Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting Tumor Microenvironment for Cancer Therapy[J]. Int J Mol Sci, 2019, 20(4):840. doi: 10.3390/ijms20040840.
[2]	Akoto T, Saini S. Role of Exosomes in Prostate Cancer Metastasis[J]. Int J Mol Sci, 2021, 22(7):3528. doi: 10.3390/ijms22073528.
[3]	Wang S, Ma F, Feng Y, et al. Role of exosomal miR-21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review)[J]. Int J Oncol, 2020, 56(5):1055-1063. doi: 10.3892/ijo.2020.4992.
[4]	Yang E, Wang X, Gong Z, et al. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression[J]. Signal Transduct Target Ther, 2020, 5(1):242. doi: 10.1038/s41392-020-00359-5.
[5]	Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance[J]. Mol Cancer, 2019, 18(1):75. doi: 10.1186/s12943-019-0991-5. pmid: 30940145
[6]	Feng W, Dean DC, Hornicek FJ, et al. Exosomes promote pre-metastatic niche formation in ovarian cancer[J]. Mol Cancer, 2019, 18(1):124. doi: 10.1186/s12943-019-1049-4. pmid: 31409361
[7]	Lim D, Do Y, Kwon BS, et al. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer[J]. BMB Rep, 2020, 53(6):291-298. doi: 10.5483/BMBRep.2020.53.6.060. pmid: 32438972
[8]	Dhani NC, Oza AM. Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer[J]. Hematol Oncol Clin North Am, 2018, 32(6):1041-1055. doi: 10.1016/j.hoc.2018.07.008.
[9]	Wu B, Zhang L, Yu Y, et al. miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis[J]. Cell Death Dis, 2020, 11(5):345. doi: 10.1038/s41419-020-2501-5. pmid: 32393810
[10]	Gavalas NG, Liontos M, Trachana SP, et al. Angiogenesis-related pathways in the pathogenesis of ovarian cancer[J]. Int J Mol Sci, 2013, 14(8):15885-15909. doi: 10.3390/ijms140815885. pmid: 23903048
[11]	Fanale D, Corsini LR, Bono M, et al. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints[J]. Crit Rev Oncol Hematol, 2024,193:104220. doi: 10.1016/j.critrevonc.2023.104220.
[12]	Ludwig N, Whiteside TL. Potential roles of tumor-derived exosomes in angiogenesis[J]. Expert Opin Ther Targets, 2018, 22(5):409-417. doi: 10.1080/14728222.2018.1464141.
[13]	Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, et al. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers[J]. Int J Mol Sci, 2020, 21(16):5840. doi: 10.3390/ijms21165840.
[14]	He L, Zhu W, Chen Q, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis[J]. Theranostics, 2019, 9(26):8206-8220. doi: 10.7150/thno.37455. pmid: 31754391
[15]	Zhao Z, Shuang T, Gao Y, et al. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization[J]. Cancer Lett, 2022, 530:45-58. doi: 10.1016/j.canlet.2022.01.011. pmid: 35051533
[16]	Masoumi-Dehghi S, Babashah S, Sadeghizadeh M. microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways[J]. J Cell Commun Signal, 2020, 14(2):233-244. doi: 10.1007/s12079-020-00548-5. pmid: 32034654
[17]	Li Z, Yan-Qing W, Xiao Y, et al. Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis[J]. J Ovarian Res, 2021, 14(1):7. doi: 10.1186/s13048-020-00758-w. pmid: 33413589
[18]	Qiu JJ, Lin XJ, Tang XY, et al. Exosomal Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer[J]. Int J Biol Sci, 2018, 14(14):1960-1973. doi: 10.7150/ijbs.28048.
[19]	Yuan D, Guo T, Zhu D, et al. Exosomal lncRNA ATB Derived from Ovarian Cancer Cells Promotes Angiogenesis via Regulating miR-204-3p/TGFβR2 Axis[J]. Cancer Manag Res, 2022, 14:327-337. doi: 10.2147/CMAR.S330368. pmid: 35115831
[20]	Wang M, Fu L, Xu Y, et al. A comprehensive overview of exosome lncRNAs: Emerging biomarkers and potential therapeutics in gynecological cancers[J]. Front Oncol, 2023,13:1138142. doi: 10.3389/fonc.2023.1138142.
[21]	Wang X, Huang J, Chen W, et al. The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer[J]. Exp Mol Med, 2022, 54(9):1390-1400. doi: 10.1038/s12276-022-00855-4.
[22]	Zhang X, Sheng Y, Li B, et al. Ovarian cancer derived PKR1 positive exosomes promote angiogenesis by promoting migration and tube formation in vitro[J]. Cell Biochem Funct, 2021, 39(2):308-316. doi: 10.1002/cbf.3583.
[23]	Yang C, Kim HS, Song G, et al. The potential role of exosomes derived from ovarian cancer cells for diagnostic and therapeutic approaches[J]. J Cell Physiol, 2019, 234(12):21493-21503. doi: 10.1002/jcp.28905. pmid: 31144314
[24]	Yunusova N, Dzhugashvili E, Yalovaya A, et al. Comparative Analysis of Tumor-Associated microRNAs and Tetraspanines from Exosomes of Plasma and Ascitic Fluids of Ovarian Cancer Patients[J]. Int J Mol Sci, 2022, 24(1):464. doi: 10.3390/ijms24010464.
[25]	Ribeiro MF, Zhu H, Millard RW, et al. Exosomes Function in Pro- and Anti-Angiogenesis[J]. Curr Angiogenes, 2013, 2(1):54-59. doi: 10.2174/22115528113020020001.
[26]	Salem KZ, Moschetta M, Sacco A, et al. Exosomes in Tumor Angiogenesis[J]. Methods Mol Biol, 2016,1464:25-34. doi: 10.1007/978-1-4939-3999-2_3.
[27]	Vera N, Acuña-Gallardo S, Grünenwald F, et al. Small Extracellular Vesicles Released from Ovarian Cancer Spheroids in Response to Cisplatin Promote the Pro-Tumorigenic Activity of Mesenchymal Stem Cells[J]. Int J Mol Sci, 2019, 20(20):4972. doi: 10.3390/ijms20204972.
[28]	Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment[J]. Semin Immunol, 2018, 35:69-79. doi: 10.1016/j.smim.2017.12.003. pmid: 29289420
[29]	Giusti I, Di Francesco M, Poppa G, et al. Tumor-Derived Extracellular Vesicles Activate Normal Human Fibroblasts to a Cancer-Associated Fibroblast-Like Phenotype, Sustaining a Pro-Tumorigenic Microenvironment[J]. Front Oncol, 2022,12:839880. doi: 10.3389/fonc.2022.839880.
[30]	Kazemi NY, Gendrot B, Berishvili E, et al. The Role and Clinical Interest of Extracellular Vesicles in Pregnancy and Ovarian Cancer[J]. Biomedicines, 2021, 9(9):1257. doi: 10.3390/biomedicines9091257.
[31]	Xu WX, Wang DD, Zhao ZQ, et al. Exosomal microRNAs shuttling between tumor cells and macrophages: cellular interactions and novel therapeutic strategies[J]. Cancer Cell Int, 2022, 22(1):190. doi: 10.1186/s12935-022-02594-y.
[32]	Mei C, Gong W, Wang X, et al. Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine[J]. Front Pharmacol, 2023,14:1147717. doi: 10.3389/fphar.2023.1147717.
[33]	Ye H, Wang RY, Yu XZ, et al. Exosomal circNFIX promotes angiogenesis in ovarian cancer via miR-518a-3p/TRIM44 axis[J]. Kaohsiung J Med Sci, 2023, 39(1):26-39. doi: 10.1002/kjm2.12615.
[34]	De A, Powers B, De A, et al. Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells[J]. Oncotarget, 2016, 7(21):31484-31500. doi: 10.18632/oncotarget.8966. pmid: 27129171
[35]	Shimizu A, Sawada K, Kimura T. Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer[J]. Cells, 2020, 9(4):814. doi: 10.3390/cells9040814.
[36]	Wang J, Wang C, Li Y, et al. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer[J]. Clin Transl Med, 2021, 11(5):e425. doi: 10.1002/ctm2.425. pmid: 34047469